{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:50:50Z","timestamp":1778068250348,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.hoc.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T08:07:37Z","timestamp":1588666057000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibody Therapy Maintenance in Follicular Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Camille","family":"Golfier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.hoc.2020.02.005_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.005_bib2","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/annonc\/mdx189","article-title":"Unmet needs in the first-line treatment of follicular lymphoma","volume":"28","author":"Casulo","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.02.005_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/1097-0142(19870715)60:2<156::AID-CNCR2820600205>3.0.CO;2-K","article-title":"The effect of intensive intermittent maintenance therapy in advanced low-grade non-Hodgkin\u2019s lymphoma","volume":"60","author":"Ezdinli","year":"1987","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.005_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/1097-0142(19880201)61:3<441::AID-CNCR2820610306>3.0.CO;2-N","article-title":"Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin\u2019s lymphoma. A randomized prospective study with an assessment of prognostic factors","volume":"61","author":"Steward","year":"1988","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.005_bib5","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.005_bib6","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.02.005_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1023\/A:1015463811683","article-title":"Cross-priming of cytotoxic T\u00a0cells promoted by apoptosis-inducing tumor cell reactive antibodies?","volume":"22","author":"Selenko","year":"2002","journal-title":"J\u00a0Clin Immunol"},{"issue":"16","key":"10.1016\/j.hoc.2020.02.005_bib8","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.005_bib9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1084\/jem.20061292","article-title":"Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis","volume":"203","author":"Roulland","year":"2006","journal-title":"J\u00a0Exp Med"},{"issue":"20","key":"10.1016\/j.hoc.2020.02.005_bib10","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin\u2019s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.005_bib11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.005_bib12","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.hoc.2020.02.005_bib13","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.005_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.02.005_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.2015.61.3968","article-title":"Rituximab maintenance for a maximum of 5 years after single-agent rituximab induction in follicular lymphoma: results of the randomized controlled phase III Trial SAKK 35\/03","volume":"34","author":"Taverna","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2020.02.005_bib16","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.005_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.hoc.2020.02.005_bib18","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.02.005_bib19","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2020.02.005_bib20","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2020.02.005_bib21","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"issue":"9759","key":"10.1016\/j.hoc.2020.02.005_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.02.005_bib23","first-page":"JCO1901073","article-title":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","author":"Bachy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2020.02.005_bib24","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.30137","article-title":"Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer Research Group (E1496)","volume":"122","author":"Barta","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.hoc.2020.02.005_bib25","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","article-title":"Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation","volume":"31","author":"Pettengell","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.005_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00277-016-2705-z","article-title":"Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience","volume":"95","author":"Bourcier","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2020.02.005_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.005_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.005_bib29","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/jnci\/djr418","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials","volume":"103","author":"Vidal","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.005_bib30","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.005_bib31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.02.005_bib32","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","article-title":"Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response","volume":"97","author":"J\u00e4ger","year":"2012","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.hoc.2020.02.005_bib33","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","article-title":"Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study","volume":"32","author":"Salar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.02.005_bib34","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9873","key":"10.1016\/j.hoc.2020.02.005_bib35","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.005_bib36","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2020.02.005_bib37","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1714337","article-title":"Obinutuzumab treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.005_bib38","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2020.02.005_bib39","first-page":"484","article-title":"Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial","volume":"130","author":"Kahl","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.02.005_bib40","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.15720","article-title":"Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma","volume":"184","author":"Hill","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2020.02.005_bib41","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3109\/10428194.2012.694429","article-title":"Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy","volume":"53","author":"Hornberger","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.hoc.2020.02.005_bib42","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.02.005_bib43","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(18)30618-1","article-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","volume":"19","author":"Trotman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"S2","key":"10.1016\/j.hoc.2020.02.005_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hon.110_2629","article-title":"Response oriented maintenance therapy in advanced follicular lymphoma. Results of the interim analysis of the FOLL12 trial conducted by Fondazione italiana Linfomi","volume":"37","author":"Federico","year":"2019","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.02.005_bib45","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:58Z","timestamp":1760184838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0889858820300307"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody Therapy Maintenance in Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}